Huperzine a activates Wnt/Β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model

Neuropsychopharmacology

Volumn 36, Issue 5, 2011, Pages 1073-1089

  Wang, Chun Yan ^a   Zheng, Wei ^a   Wang, Tao ^a   Xie, Jing Wei ^a   Wang, Si Ling ^b   Zhao, Bao Lu ^c   Teng, Wei Ping ^a   Wang, Zhan You ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c INSTITUTE OF BIOPHYSICS   (China)

Author keywords

catenin; Alzheimer's disease; APP PS1 transgenic mouse; glycogen synthase kinase; huperzine A; Wnt signaling

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CATENIN; HUPERZINE A; PRESENILIN 1; WNT PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOUSE; MUTATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSGENIC MOUSE;

ACETYLCHOLINESTERASE; ALKALOIDS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; BETA CATENIN; BLOOD-RETINAL BARRIER; BROMODEOXYURIDINE; CELL SURVIVAL; CHOLINESTERASE INHIBITORS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; MUTATION; NERVE TISSUE PROTEINS; NEUROBLASTOMA; NEUROGENESIS; OLFACTORY BULB; PRESENILIN-1; RNA, MESSENGER; SESQUITERPENES; SIGNAL TRANSDUCTION; TRANSFECTION; WNT PROTEINS;

EID: 79952756491     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.245     Document Type: Article

References (79)

1. Akaike A, Takada-Takatori Y, Kume T, Izumi Y (2010). Mechanisms of neuroprotective effects of nicotine and acetylcholines-terase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J Mol Neurosci 40: 211-216.
2. Alisky JM (2006). Cholinesterase inhibitors might alleviate methamphetamine-induced delusions, hallucinations and cognitive impairment, while reducing craving and addiction. World J Biol Psychiatry 7: 269.
3. Alvarez A, Alarcon R, Opazo C, Campos EO, Munoz FJ, Calderon FH et al (1998). Stable complexes involving acetylcho-linesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 18: 3213-3223. (Pubitemid 28186014)
4. Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC (1997). Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 272: 348-361. (Pubitemid 27410049)
5. Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC (2004). Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 297: 186-196. (Pubitemid 38759572)
6. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J (1999). Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 453: 260-264. (Pubitemid 29326659)
7. Baum L, Hansen L, Masliah E, Saitoh T (1996). Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofi-brillary tangle formation. Mol Chem Neuropathol 29: 253-261. (Pubitemid 27016933)
8. Bodles AM, Barger SW (2005). Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK. Neurobiol Aging 26: 9-16. (Pubitemid 39600586)
9. Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A et al (2004). Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 24: 6021-6027. (Pubitemid 38859398)
10. Ceravolo R, Volterrani D, Tognoni G, Dell'Agnello G, Manca G, Kiferle L et al (2004). Cerebral perfusional effects of cholinester-ase inhibitors in Alzheimer disease. Clin Neuropharmacol 27: 166-170. (Pubitemid 39121728)
11. Chen RH, Ding WV, McCormick F (2000). Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. J Biol Chem 275: 17894-17899. (Pubitemid 30430843)
12. Cheng DH, Ren H, Tang XC (1996). Huperzine A, a novel promising acetylcholinesterase inhibitor. NeuroReport 8: 97-101. (Pubitemid 126785539)
13. Cheng DH, Tang XC (1998). Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 60: 377-386. (Pubitemid 28282678)
14. Cook D, Fry MJ, Hughes K, Sumathipala R, Woodgett JR, Dale TC (1996). Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a protein kinase C. EMBO J 15: 4526-4536. (Pubitemid 26294571)
15. De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G et al (2003). Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 8: 195-208. (Pubitemid 36315228)
16. Erkinjuntti T, Roman G, Gauthier S (2004). Treatment of vascular dementiaFevidence from clinical trials with cholinesterase inhibitors. J Neurol Sci 226: 63-66. (Pubitemid 39505408)
17. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T et al (1990). Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248: 1122-1124.
18. Farias GG, Godoy JA, Vazquez MC, Adani R, Meshulam H, Avila J et al (2005). The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol Dis 18: 176-183. (Pubitemid 40092907)
19. Garrido JL, Godoy JA, Alvarez A, Bronfman M, Inestrosa NC (2002). Protein kinase C inhibits amyloid beta peptide neuro-toxicity by acting on members of the Wnt pathway. FASEB J 16: 1982-1984.
20. Geula C, Mesulam MM (1995). Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 9(Suppl 2): 23-28.
21. Guillozet AL, Smiley JF, Mash DC, Mesulam MM (1997). Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42: 909-918. (Pubitemid 28008422)
22. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL et al (1992). Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359: 322-325.
23. Holick KA, Lee DC, Hen R, Dulawa SC (2008). Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 33: 406-417. (Pubitemid 350243341)
24. Inestrosa NC, Alvarez A, Dinamarca MC, Perez-Acle T, Colombres M (2005). Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway. Curr Alzheimer Res 2: 301-306. (Pubitemid 40980188)
25. Inestrosa NC, Alvarez A, Godoy J, Reyes A, De Ferrari GV (2000). Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity. Acta Neurol Scand Suppl 176: 53-59. (Pubitemid 32156171)
26. Inestrosa NC, Dinamarca MC, Alvarez A (2008a). Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. FEBS J 275: 625-632. (Pubitemid 351160969)
27. Inestrosa NC, Toledo EM (2008b). The role of Wnt signaling in neuronal dysfunction in Alzheimer's disease. Mol Neurodegener 3: 9.
28. Inestrosa NC, Urra S, Colombres M (2004). Acetylcholinesterase (AChE)-amyloid-beta-peptide complexes in Alzheimer's disease. The Wnt signaling pathway. Curr Alzheimer Res 1: 249-254.
29. Kim WR, Kim Y, Eun B, Park OH, Kim H, Kim K et al (2007). Impaired migration in the rostral migratory stream but spared olfactory function after the elimination of programmed cell death in Bax knock-out mice. J Neurosci 27: 14392-14403.
30. Kuhn HG, Dickinson-Anson H, Gage FH (1996). Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci 16: 2027-2033. (Pubitemid 26144015)
31. Lahiri DK, Rogers JT, Greig NH, Sambamurti K (2004). Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 10: 3111-3119. (Pubitemid 39242906)
32. Lahoud-Rahme MS, Stezoski J, Kochanek PM, Melick J, Tisherman SA, Drabek T (2009). Blood-brain barrier integrity in a rat model of emergency preservation and resuscitation. Resuscitation 80: 484-488.
33. Lenzser G, Kis B, Snipes JA, Gaspar T, Sandor P, Komjati K et al (2007). Contribution of poly(ADP-ribose) polymerase to post-ischemic blood-brain barrier damage in rats. J Cereb Blood Flow Metab 27: 1318-1326. (Pubitemid 46985348)
34. Leonard AK, Sileno AP, Brandt GC, Foerder CA, Quay SC, Costantino HR (2007). In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm 335: 138-146. (Pubitemid 46482873)
35. Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ et al (2006). Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 83: 374-384. (Pubitemid 43184401)
36. Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA (2009). Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J Neurosci 29: 6734-6751.
37. Mattson MP, Barger SW, Furukawa K, Bruce AJ, Wyss-Coray T, Mark RJ et al (1997). Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res Brain Res Rev 23: 47-61. (Pubitemid 27090749)
38. Moon RT, Bowerman B, Boutros M, Perrimon N (2002). The promise and perils of Wnt signaling through beta-catenin. Science 296: 1644-1646. (Pubitemid 34579151)
39. Mori E, Hashimoto M, Krishnan KR, Doraiswamy PM (2006). What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? Alzheimer Dis Assoc Disord 20(2 Suppl 1): S 19-S 26. (Pubitemid 44305905)
40. Munoz FJ, Inestrosa NC (1999). Neurotoxicity of acetylcholines-terase amyloid beta-peptide aggregates is dependent on the type of Abeta peptide and the AChE concentration present in the complexes. FEBS Lett 450: 205-209. (Pubitemid 29219515)
41. Muyllaert D, Terwel D, Borghgraef P, Devijver H, Dewachter I, Van Leuven F (2006). Transgenic mouse models for Alzheimer's disease: the role of GSK-3B in combined amyloid and tau-pathology. Rev Neurol (Paris) 162: 903-907. (Pubitemid 44495481)
42. Patapoutian A, Reichardt LF (2000). Roles of Wnt proteins in neural development and maintenance. Curr Opin Neurobiol 10: 392-399. (Pubitemid 30389308)
43. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B et al (1999). Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibril-lary changes. J Neuropathol Exp Neurol 58: 1010-1019. (Pubitemid 29441929)
44. Peng Y, Jiang L, Lee DY, Schachter SC, Ma Z, Lemere CA (2006). Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells. J Neurosci Res 84: 903-911. (Pubitemid 44366691)
45. Peng Y, Lee DY, Jiang L, Ma Z, Schachter SC, Lemere CA (2007). Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695. Neuroscience 150: 386-395. (Pubitemid 350199698)
46. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003). GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439. (Pubitemid 36626994)
47. Racchi M, Mazzucchelli M, Porrello E, Lanni C, Govoni S (2004). Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 50: 441-451. (Pubitemid 39089089)
48. Reyes AE, Chacon MA, Dinamarca MC, Cerpa W, Morgan C, Inestrosa NC (2004). Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astro-cytosis, and neuronal cell loss. Am J Pathol 164: 2163-2174. (Pubitemid 38669363)
49. Rochefort C, Gheusi G, Vincent JD, Lledo PM (2002). Enriched odor exposure increases the number of newborn neurons in the adult olfactory bulb and improves odor memory. J Neurosci 22: 2679-2689. (Pubitemid 37465817)
50. Sheldahl LC, Park M, Malbon CC, Moon RT (1999). Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr Biol 9: 695-698. (Pubitemid 29332351)
51. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM et al (1992). Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258: 126-129.
52. Sicras A, Rejas-Gutierrez J (2004). Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine. Rev Neurol 39: 312-316. (Pubitemid 39312110)
53. Tang LL, Wang R, Tang XC (2005). Huperzine A protects SHSY5Y neuroblastoma cells against oxidative stress damage via nerve growth factor production. Eur J Pharmacol 519: 9-15. (Pubitemid 43181158)
54. Tang W, Zhang Y, Gao J, Ding X, Gao S (2008). The anti-fatigue effect of 20(R)-ginsenoside Rg3 in mice by intranasally administration. Biol Pharm Bull 31: 2024-2027.
55. Toledo EM, Colombres M, Inestrosa NC (2008). Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol 86: 281-296.
56. Turker S, Onur E, Ozer Y (2004). Nasal route and drug delivery systems. Pharm World Sci 26: 137-142. (Pubitemid 39012580)
57. Van Der Staay FJ, Bouger PC (2005). Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats. Behav Brain Res 156: 1-10. (Pubitemid 39330431)
58. Ved HS, Koenig ML, Dave JR, Doctor BP (1997). Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. NeuroReport 8: 963-968. (Pubitemid 27152155)
59. Wallace WC, Akar CA, Lyons WE (1997). Amyloid precursor protein potentiates the neurotrophic activity of NGF. Brain Res Mol Brain Res 52: 201-212. (Pubitemid 28043463)
60. Wang LM, Han YF, Tang XC (2000). Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur J Pharmacol 398: 65-72. (Pubitemid 30336678)
61. Wang R, Yan H, Tang XC (2006a). Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 27: 1-26. (Pubitemid 43051942)
62. Wang R, Zhang HY, Tang XC (2001). Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur J Pharmacol 421: 149-156. (Pubitemid 32539415)
63. Wang ZF, Tang LL, Yan H, Wang YJ, Tang XC (2006b). Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol Biochem Behav 83: 603-611. (Pubitemid 43817131)
64. Wang ZF, Tang XC (2007). Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation-induced injury. FEBS Lett 581: 596-602. (Pubitemid 46216285)
65. Wang ZF, Wang J, Zhang HY, Tang XC (2008). Huperzine A exhibits anti-inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. J Neurochem 106: 1594-1603.
66. Willert K, Nusse R (1998). Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev 8: 95-102. (Pubitemid 28122147)
67. Yagi N, Taniuchi Y, Hamada K, Sudo J, Sekikawa H (2002). Pharmacokinetics of ketotifen fumarate after intravenous, intranasal, oral and rectal administration in rabbits. Biol Pharm Bull 25: 1614-1618. (Pubitemid 39663680)
68. Yan H, Zhang HY, Tang XC (2007). Involvement of M1-muscarinic acetylcholine receptors, protein kinase C and mitogen-activated protein kinase in the effect of huperzine A on secretory amyloid precursor protein-alpha. NeuroReport 18: 689-692. (Pubitemid 46608516)
69. Yu S, Zheng W, Xin N, Chi ZH, Wang NQ, Nie YX et al (2010). Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Res 13: 55-64.
70. Yue P, Tao T, Zhao Y, Ren J, Chai X (2007). Huperzine A in rat plasma and CSF following intranasal administration. Int J Pharm 337: 127-132. (Pubitemid 46756039)
71. Zhang HY, Tang XC (2006). Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 27: 619-625. (Pubitemid 44738090)
72. Zhang HY, Yan H, Tang XC (2004). Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett 360: 21-24. (Pubitemid 38471978)
73. Zhang HY, Yan H, Tang XC (2008a). Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol 28: 173-183. (Pubitemid 351253069)
74. Zhang HY, Zheng CY, Yan H, Wang ZF, Tang LL, Gao X et al (2008b). Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Chem Biol Interact 175: 396-402.
75. Zhang J, Liu Q, Chen Q, Liu NQ, Li FL, Lu ZB et al (2006a). Nicotine attenuates beta-amyloid-induced neurotoxicity by regulating metal homeostasis. FASEB J 20: 1212-1214.
76. Zhang J, Mori A, Chen Q, Zhao B (2006b). Fermented papaya preparation attenuates beta-amyloid precursor protein: beta-amyloid-mediated copper neurotoxicity in beta-amyloid precursor protein and beta-amyloid precursor protein Swedish mutation overexpressing SH-SY5Y cells. Neuroscience 143: 63-72. (Pubitemid 44667306)
77. Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M et al (1998). Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395: 698-702. (Pubitemid 28475966)
78. Zheng W, Xin N, Chi ZH, Zhao BL, Zhang J, Li JY et al (2009). Divalent metal transporter 1 is involved in amyloid precursor protein processing and Abeta generation. FASEB J 23: 4207-4217.
79. Zhu XD, Giacobini E (1995). Second generation cholinesterase inhibitors: effect of (L)-huperzine-A on cortical biogenic amines. J Neurosci Res 41: 828-835.